Kymera Therapeutics (KYMR) Tops Q4 EPS by 15c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.25), $0.15 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $47.9 million versus the consensus estimate of $41.94 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits